{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000023","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.943913+00:00","generated_at":"2026-06-27T14:22:04.803731+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Xeris files Strongbridge unaudited 9M 2021 financials: net loss $31.6M, rev $29.9M","bullets":["Strongbridge nine months ended Sep 30, 2021: net loss $31.6M vs $33.1M prior-year.","Revenue $29.9M vs $22.5M prior-year, primarily from Keveyis sales.","Cash and equivalents $55.3M; accumulated deficit $337.2M as of Sep 30, 2021.","Acquisition by Xeris closed Oct 5, 2021; filing satisfies SEC requirement for acquired company financial statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000023","json":"https://secwatch.observer/filing/0001867096-22-000023.json","markdown":"https://secwatch.observer/filing/0001867096-22-000023.md","text":"https://secwatch.observer/filing/0001867096-22-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/0001867096-22-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/xers-20220128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T14:22:04.803731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}